Physician profile
Deborah Peter
NPI 1124512686
$12,255.88
in general payments reported to CMS, 2019-2025
41 companies · $3,481 in 2025
The $3,481 reported for 2025 was more than what 98% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $1,298 · 2023: $1,212 · 2024: $5,832 · 2025: $3,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,575 · Travel and Lodging: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,575.00 |
| Travel and Lodging | $1,169.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,773.28 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $1,624.32 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Novo Nordisk INC | $1,006.55 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $541.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $480.70 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $432.71 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $355.47 | 2023-2025 | Korlym |
| Abbott Laboratories | $326.51 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $312.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.51 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $212.64 | 2022-2025 | |
| Abbvie INC. | $199.61 | 2022-2025 | |
| Amgen INC. | $180.34 | 2022-2025 | Evenity, Tepezza, Prolia |
| Cequr Corporation | $155.56 | 2022-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $151.27 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $129.66 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Chiesi USA, INC. | $111.62 | 2024-2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $95.67 | 2023-2025 | Yorvipath |
| Kite Pharma, INC. | $94.58 | 2025 | Yescarta |
| Mannkind Corporation | $84.03 | 2023-2025 | Afrezza |
| Astrazeneca Pharmaceuticals Lp | $78.36 | 2022-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $68.30 | 2021-2025 | Strensiq |
| Ibsa Pharma INC. | $58.39 | 2022-2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $57.36 | 2024 | |
| Recordati_rare_diseases_inc. | $44.33 | 2021-2025 | Isturisa |
| Lifescan, INC. | $43.18 | 2022 | |
| Currax Pharmaceuticals LLC | $39.42 | 2021-2023 | Onzetra Xsail, Contrave |
| Insulet Corporation | $37.77 | 2022-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $32.02 | 2023 | Steglatro, Verquvo, Steglujan |
| Amneal Pharmaceuticals LLC | $29.20 | 2024-2025 | Unithroid |
| Sequel Med Tech, LLC | $29.20 | 2025 | Twiist |
| Nevro Corp. | $23.64 | 2024 | Senza |
| Neurocrine Biosciences, INC. | $23.31 | 2025 | |
| Baxter Healthcare | $22.25 | 2025 | Perclot |
| Novartis Pharmaceuticals Corporation | $21.61 | 2024 | |
| Endo Pharmaceuticals INC. | $19.23 | 2022 | |
| Echosens North America, INC. | $18.94 | 2024 | Fibroscan |
| Amryt Pharma Holdings Ltd | $18.93 | 2022 | |
| Hologic Sales and Service, LLC | $18.28 | 2023 | Coolseal Generator |
| Paratek Pharmaceuticals, INC. | $16.49 | 2025 | Nuzyra |
| Boston Scientific Corporation | $15.68 | 2025 | Cre Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Peter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.